These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32739722)

  • 1. Fingolimod-induced immune thrombocytopenic purpura (ITP).
    Mukharesh L; Rothstein TL
    Clin Neurol Neurosurg; 2020 Oct; 197():106081. PubMed ID: 32739722
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune thrombocytopenic purpura associated with fingolimod.
    Yuen HLA; Brown S; Chan N; Grigoriadis G
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28893804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of adults with autoimmune thrombocytopenic purpura.
    Newland AC
    Lancet; 2002 Jan; 359(9300):4-5. PubMed ID: 11809175
    [No Abstract]   [Full Text] [Related]  

  • 5. Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    Guerrieri S; Rubin M; Gattuso I; Zanetta C; Genchi A; Preziosa P; Rocca MA; Filippi M; Moiola L
    J Neurol; 2024 Jun; 271(6):3678-3681. PubMed ID: 38564055
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
    Wills A; Fan G; Kim E; Okada CY; White KP; Hopkins RS
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous immunoglobulin and high dose anti-D immunoglobulin as initial therapy for childhood immune thrombocytopenic purpura.
    Ozsoylu S
    Br J Haematol; 2011 Mar; 152(6):783-4. PubMed ID: 21275947
    [No Abstract]   [Full Text] [Related]  

  • 9. Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?
    London F; Cambron B; Jacobs S; Delrée P; Gustin T
    Mult Scler Relat Disord; 2020 Jun; 41():102012. PubMed ID: 32088655
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity.
    Güngör T; Arman Bilir Ö; Koşan Çulha V; Güngör A; Kara A; Azık FM; Yaralı HN
    Pediatr Neonatol; 2019 Aug; 60(4):411-416. PubMed ID: 30470618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITP: tolerance lost.
    Fogarty PF
    Blood; 2011 Dec; 118(24):6232-4. PubMed ID: 22161847
    [No Abstract]   [Full Text] [Related]  

  • 12. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura.
    Erduran E; Aslan Y; Gedik Y; Orhan F
    Turk J Pediatr; 2003; 45(4):295-300. PubMed ID: 14768792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous immunoglobulin or megadose methylprednisolone for the treatment of idiopathic thrombocytopenic purpura.
    Ozsoylu S
    Am J Pediatr Hematol Oncol; 1991; 13(3):364-5. PubMed ID: 1817495
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group.
    Rosthøj S; Nielsen S; Pedersen FK
    Acta Paediatr; 1996 Aug; 85(8):910-5. PubMed ID: 8863869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of adult's immune thrombopenia (ITP)].
    Khellaf M
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S329-32. PubMed ID: 21056519
    [No Abstract]   [Full Text] [Related]  

  • 20. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.